Walking With Overground Robotic Exoskeleton Device to Increase Behavioral Responsiveness in Patients With Disorders of Consciousness (WALK DOC) (WALK DOC)
13 de julho de 2026 atualizado por: Chad, Swank, Spaulding Rehabilitation Hospital
The goal of this observational study is to learn whether walking with an overground robotic exoskeleton (ORE) can improve responsiveness and brain activity in adults with disorders of consciousness (DoC) during inpatient rehabilitation after a severe brain injury. Participants include adults ages 18-70 who are in a coma, unresponsive wakefulness syndrome, or minimally conscious state and are receiving rehabilitation care at Spaulding Rehabilitation Hospital.
The main questions it aims to answer are:
- Does using an ORE improve behavioral responsiveness compared with lying down, sitting, or standing?
- Does using an ORE increase brain activity, and are changes in brain activity related to changes in responsiveness?
- Is ORE therapy safe, tolerable, and feasible for people with DoC during inpatient rehabilitation?
Researchers will compare participants' responses during sessions involving lying down, sitting, standing, and walking with the robotic exoskeleton to see if the exoskeleton leads to greater improvements in responsiveness and brain activity.
Participants will:
- Complete an initial screening session to determine whether they can safely use the robotic exoskeleton.
- Participate in six study sessions over about two weeks during their rehabilitation stay. During these sessions, participants will complete activities that may include lying down, sitting, standing, and walking with a robotic exoskeleton. The order of activities will be assigned at random.
- Have their level of responsiveness measured before and after each session using a standardized assessment called the Coma Recovery Scale-Revised (CRS-R).
- Wear a wireless EEG cap before, during, and after sessions so researchers can measure brain activity.
- Have their heart rate and safety monitored throughout the study sessions.
Visão geral do estudo
Status
Ainda não está recrutando
Intervenção / Tratamento
Tipo de estudo
Observacional
Inscrição (Estimado)
18
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Jenny Zhang, MS
- Número de telefone: 6179526354
- E-mail: jzhang71@mgb.org
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02129
- Spaulding Rehabilitation Hospital
-
Investigador principal:
- Chad Swank, PhD
-
Contato:
- Clinical Research Project Manager
- Número de telefone: 6179526354
- E-mail: jzhang71@mgb.org
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Método de amostragem
Amostra Não Probabilística
População do estudo
The study population will be selected from inpatient rehabilitation patients with disorders of consciousness (DoC) receiving medical care and rehabilitation at inpatient rehabilitation units in an inpatient rehabilitation facility (IRF) or long-term acute care hospital (LTAC).
Patients will be identified from those admitted for inpatient rehabilitation and screened using the eligibility criteria outlined, through the hospital's standard clinical and medical record review processes.
Descrição
Inclusion Criteria:
- Medical diagnosis of disorders of consciousness (DoC) confirmed by the Coma Recovery Scale - Revised (CRS-R), including patient classified as Minimally Conscious State (MCS), Unresponsive Wakefulness Syndrome (UWS), or coma.
- Acute/Subacute phase of recovery
- Medically stable as deemed by a physician
- Undergoing medical care and rehabilitation at hospital
- Both sexes and all races and ethnicities
- Meet the robotic exoskeleton frame limitations
- Continence of or a program for bladder and bowel management
Exclusion Criteria:
- Concurrent spinal cord injury (SCI)
- Degenerative diagnoses, pre-morbid developmental disability, significant psychological diagnosis such as bipolar disorder and schizophrenia
- Any contraindication to use the exoskeleton device, including:
- Contracture in the hip, knee and ankle joints.
- Uncorrectable Equinovarus foot deformation.
- Severe muscular spasticity of the lower extremities (Modified Ashworth Scale Grade 3 higher).
- Fractures or incomplete bone junctions in the spine, pelvis, and/or lower extremities.
- Osteoporosis or lower bone mineral density -3.5, and history(ies) of osteoporotic fracture(s).
- Skin disorders including Stage I pressure injuries at the hip, lower limbs, and Exoskeleton contact areas, according to the National and European Pressure Ulcer Classification System (NPUAP-EPUAP).
- Inability to communicate with an Assistant due to cognitive and language disorders.
- Severe arthritis, acute arthritis, or synovitis after total or partial lower limb joint replacement.
- Orthostatic hypotension, essential hypertension, and a condition in which blood pressure is not controlled.
- Myocardial infarction or angina or ischemic heart disease within the last 6 months.
- Tachycardia, bradycardia, arrhythmia and other cardiac functions that are not controlled.
- Uncontrolled autonomic dysreflexia (AD).
- Uncontrolled diabetes.
- Infectious diseases or other serious complications.
- Uncorrectable leg length discrepancy over 2 cm when using additional correction tools.
- III-IV spine scoliotic deformity.
- Pregnant women should consult their physician prior to use.
- Amputations and lower limb prostheses.
- Morphological characteristics out of the device limitations.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Patients with Disorders of Consciousness
Adults with a disorder of consciousness, such as coma, unresponsive wakefulness syndrome, or a minimally conscious state, who are receiving inpatient rehabilitation after a severe brain injury.
|
Participants will receive overground robotic exoskeleton-assisted standing and walking as part of inpatient rehabilitation.
Following a screening session to assess device fit and tolerance, participants complete supervised ORE sessions.
The intervention is distinguished by the use of assisted overground walking and upright mobility in individuals with disorders of consciousness and is evaluated in relation to behavioral responsiveness, brain activity, safety, tolerability, and feasibility.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Coma Recovery Scale-Revised (CRS-R)
Prazo: From enrollment to end of study at 2 weeks
|
The Coma Recovery Scale-Revised (CRS-R) is a 23-item behavioral assessment used to evaluate consciousness in patients with brain injuries.
It measures auditory, visual, motor, oromotor, and communication functions.
The total score ranges from a minimum of 0 to a maximum of 23, with higher scores indicating a higher level of neurobehavioral function and conscious awareness.
CRS-R scores help characterize a patient's level of consciousness, including coma, vegetative state/unresponsive wakefulness syndrome, or minimally conscious state.
|
From enrollment to end of study at 2 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Disability Rating Scale (DRS)
Prazo: Discharge from inpatient rehabilitation, an average of 8 weeks
|
The Disability Rating Scale (DRS) is an 8-item clinical tool used to track a patient's recovery from a moderate-to-severe traumatic brain injury (TBI) from the coma stage through to community living.
Scores range from 0 (no disability) to 29 (extreme vegetative state)
|
Discharge from inpatient rehabilitation, an average of 8 weeks
|
|
CARE (Continuity Assessment Record and Evaluation)
Prazo: From inpatient admission through discharge from inpatient stay, assessed at routine intervals.
|
The CARE (Continuity Assessment Record and Evaluation) tool is a standardized CMS assessment used to measure the medical, functional, cognitive, and social needs of Medicare post-acute care patients The assessment evaluates four major domains:
|
From inpatient admission through discharge from inpatient stay, assessed at routine intervals.
|
|
Electroencephalogram (EEG)
Prazo: Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
|
Cortical activity will be recorded continuously during the study sessions using a 24-channel mobile electroencephalography (EEG) system.
Key positional changes will be marked in the EEG recording.
EEG spectral power, including power within predefined brain wave frequency bands, will be evaluated before, during, and after positional changes.
Changes in these measures will be used to evaluate cortical activity across study conditions.
EEG frequency measures will be reported in hertz (Hz).
|
Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
|
|
Event-Related Potential (ERP) - N100
Prazo: Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
|
Event-related potentials (ERP) will be recorded before and immediately after each study session.
N100 ERP responses will be assessed, reflecting auditory sensory processing.
For each response, the timing of the brain response (peak latency) will be measured.
ERP latency measures will be reported in milliseconds (ms).
|
Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
|
|
Event-Related Potential (ERP) - P300
Prazo: Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
|
Event-related potentials (ERP) will be recorded before and immediately after each study session.
P300 ERP responses will be assessed, reflecting basic attention processing.
For each response, the timing of the brain response (peak latency) will be measured.
ERP latency measures will be reported in milliseconds (ms).
|
Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
|
|
Event-Related Potential (ERP) - N400
Prazo: Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
|
Event-related potentials (ERP) will be recorded before and immediately after each study session.
N400 ERP responses will be assessed, reflecting cognitive processing.
For each response, the timing of the brain response (peak latency) will be measured.
ERP latency measures will be reported in milliseconds (ms).
|
Measured throughout 6 study assessment sessions conducted over 2 weeks during inpatient rehabilitation.
|
|
Rate of Adverse Events (AE)
Prazo: Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.
|
Safety of the study will be measure via Rate of Adverse Events (AE).
Reported exoskeleton-emergent AE will include: increase in pain behavior or agitation, disconcerting changes in cardiovascular function (e.g., sudden drop in blood pressure), skin irritation or orthopedic injuries caused by the robotic exoskeleton device, sudden changes in alertness (e.g., somnolence), autonomic storming, and seizure activity.
|
Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.
|
|
Heart Rate Reserve (HRR)
Prazo: Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.
|
Heart Rate Reserve (HRR) will be recorded as a measure of cardiovascular tolerability during the intervention.
A heart rate monitor will be used to record the amount of time spent in each heart rate zone during ORE sessions: very light (<30% HRR), light (30-39%), moderate (40-59%), vigorous (60-89%), and near maximal (>90%).
|
Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.
|
|
Session completion rate (SCR)
Prazo: Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.
|
Session completion rate (SCR) will be used to assess the feasibility of completing the scheduled overground robotic exoskeleton sessions.
Feasibility will be measured by the percentage of scheduled sessions that each participant completes.
Based on prior clinical experience delivering exoskeleton sessions to patients with disorders of consciousness, successful session completion will be defined as completing at least 75% of the scheduled overground robotic exoskeleton sessions.
For any missed session, the reason for the missed session and whether the session was rescheduled or made up will be documented.
The time needed to complete any make-up sessions will also be recorded.
These data will help determine whether the intervention schedule is practical and manageable for participants.
|
Measured throughout study participation, including during 6 study assessment sessions conducted over 2 weeks and at routine intervals as part of standard clinical care during inpatient rehabilitation.
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Chad Swank, PhD, Spaulding Rehabilitation Hospital
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de agosto de 2026
Conclusão Primária (Estimado)
1 de abril de 2028
Conclusão do estudo (Estimado)
1 de outubro de 2028
Datas de inscrição no estudo
Enviado pela primeira vez
7 de julho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
13 de julho de 2026
Primeira postagem (Real)
16 de julho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
16 de julho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
13 de julho de 2026
Última verificação
1 de julho de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2026P000662
- HT94252510986 (Número de outro subsídio/financiamento: CDMRP)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Sim
produto fabricado e exportado dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .